Specialty Drug Strategy in a High-Cost, High-Scrutiny Environment
Key Takeaways
- Specialty pipeline growth is accelerating. Oncology, rare disease, and cell and gene therapies are expected to dominate launches through 2027, increasing cost concentration and financial risk for payers.1
- Management tools must evolve. Traditional formulary controls are being supplemented with tighter utilization management, biosimilar strategies, and outcomes-based contracting.
- Strategic recalibration is underway. Pipeline forecasting, real-world evidence, and value-based reimbursement models are becoming essential to sustain access while maintaining affordability.
The specialty drug pipeline is expanding at a pace that is reshaping managed care strategy. A November 2025 Advisory Board analysis projects that specialty therapies—particularly in oncology, rare diseases, and advanced gene-based treatments—will account for a significant share of new launches through 2027.1 As innovation increasingly centers on high-cost, highly targeted therapies, health plans and pharmacy benefit managers (PBMs) face mounting pressure to manage both financial exposure and patient access.
Oncology remains a dominant force within the late-stage pipeline, driven by advances in immunotherapy, precision medicine, and antibody-drug conjugates. Rare disease development also continues to surge, often accompanied by significant upfront pricing tied to small patient populations and complex manufacturing processes.1 These trends create a concentrated spend environment in which even limited utilization can materially affect plan budgets.
Evolving Utilization and Formulary Management
In response to pipeline growth and rising spend, managed care organizations are reevaluating specialty management frameworks. Traditional formulary exclusion strategies may be less viable in categories where few therapeutic alternatives exist. Instead, payers are increasingly emphasizing refined prior authorization criteria, evidence-based step therapy protocols, and site-of-care optimization to manage total cost of care.
Biosimilar adoption remains a critical lever in therapeutic areas where competition is available, offering opportunities to moderate spend without compromising outcomes. However, in areas with limited therapeutic substitutes—such as certain gene and rare disease therapies—plans must rely more heavily on rigorous clinical review and structured access pathways.
Expanding Role of Value-Based Contracting
The growth of novel and gene-based therapies introduces additional uncertainty regarding long-term clinical benefit and durability. In these scenarios, value-based contracting (VBC) arrangements tied to real-world performance metrics may offer a pathway to share risk between payers and manufacturers.
By linking reimbursement to outcomes such as adherence, hospitalization rates, or sustained clinical response, stakeholders can better align payment with demonstrated value. As specialty costs rise, performance-based reimbursement models are increasingly viewed as tools to manage uncertainty while preserving patient access.
Heightened Scrutiny and Strategic Dialogue
The expanding specialty landscape is also drawing increased scrutiny from policymakers and employer sponsors concerned about affordability and transparency. As more high-cost therapies move into broader patient populations, stakeholders are under greater pressure to demonstrate that management strategies are both clinically sound and financially sustainable.
Given these dynamics, specialty drug strategy is likely to be a prominent topic of discussion at the Pharmaceutical Care Management Association (PCMA) 2026 Business Forum. Senior leaders across PBMs, payers, specialty pharmacies, and pharmaceutical manufacturers are expected to examine how pipeline trends are influencing bid modeling, formulary design, and contracting strategies in the years ahead.
Looking Ahead
As specialty innovation continues to accelerate, managed care organizations must adopt more agile and data-driven frameworks to navigate rising costs and therapeutic complexity. Integrating pipeline forecasting, disciplined utilization management, and performance-based reimbursement models will be essential to balancing innovation, access, and long-term sustainability.
Reference
- Bakst C, Simmons K, Abraha B. The 3 trends reshaping the specialty drug pipeline today. Advisory Board. Published November 2025. Accessed March 10, 2026. https://www.advisory.com/content/dam/advisory/en/public/content-resources/2025/specialty-drug-pipeline-ei.pdf.coredownload.pdf
